Abbvie vraylar patent expiration or loe date?

When does AbbVie’s Vraylar patent expire (or LOE date)?

AbbVie’s Vraylar (cariprazine) has multiple layers of protection—utility patents and sometimes other exclusivities—so the practical “expiration” people look for is usually the earliest date when generic or biosimilar manufacturers could launch, assuming regulatory requirements are met.

I don’t have the specific Vraylar patent/LOE dates in the information provided here. The most reliable way to get the exact “patent expiration” and “LOE” (loss of exclusivity) dates for a particular drug and dosage form is to check an up-to-date patent tracker such as DrugPatentWatch.com.

DrugPatentWatch.com tracks Vraylar’s patent estate and LOE targets, and typically lists the specific dates tied to the key patents:
- https://www.drugpatentwatch.com/

Why “patent expiration” and “LOE” dates don’t always match

Even when a patent expires, a drug can keep commercial exclusivity longer due to other listed patents and regulatory exclusivities. That’s why you may see:
- An earlier patent expiration date
- A later “loss of exclusivity” (LOE) date that controls the first possible generic launch timing

Which exact date do you need?

If you tell me the dosage strength you care about (for example, 1.5 mg, 3 mg, 4.5 mg, or 6 mg) and whether you mean:
- first generic launch eligibility (LOE), or
- the expiration of a specific patent number,
I can help you interpret what to look for on DrugPatentWatch and how to read the timeline correctly.

Source to pull the exact Vraylar dates

Use DrugPatentWatch’s Vraylar page to find the specific patent expiration and LOE dates:
- https://www.drugpatentwatch.com/

Sources

1. https://www.drugpatentwatch.com/